LNTH News

Lantheus Holdings, Inc. Class Action: Levi & Korsinsky Reminds Lantheus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 - LNTH

Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease

LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Lantheus Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 10, 2025 to Discuss Your Rights - LNTH

Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

LNTH Deadline: LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit

Lantheus Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 10, 2025 to Discuss Your Rights - LNTH

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - LNTH

The Gross Law Firm Reminds Lantheus Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 - LNTH